Overview

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this Phase 3 study is to assess the pharmacokinetics of rVWF:rFVIII and rVWF, and to assess the safety and efficacy of rVWF:rFVIII and rVWF in the treatment of bleeding events in subjects with severe hereditary von Willebrand disease (VWD).

Phase:

Phase 3

Details

Lead Sponsor:

Baxalta now part of Shire
Baxalta US Inc.

Treatments:

Factor VIII